Pfeffer M A, Domanski M, Rosenberg Y, Verter J, Geller N, Albert P, Hsia J, Braunwald E
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Am J Cardiol. 1998 Aug 6;82(3A):25H-30H. doi: 10.1016/s0002-9149(98)00488-3.
The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo-controlled trial designed to determine the usefulness of angiotensin-converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction > or =40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.
血管紧张素转换酶抑制预防事件（PEACE）试验是一项纳入8100例患者的随机、双盲、安慰剂对照试验，旨在确定血管紧张素转换酶（ACE）抑制剂在治疗左心室射血分数保留的冠心病患者中的效用。该试验所检验的假设是，与接受传统治疗的患者相比，接受ACE抑制剂治疗的冠心病且射血分数≥40%的患者，其心血管死亡、非致死性心肌梗死或血运重建术的发生率将降低。本文描述了PEACE试验的设计。
